NCT06770933: An ongoing trial by Vantage Biosciences Ltd
This trial is ongoing. It must report results 1 year, 11 months from now.
Full data
| Full entry on ClinicalTrials.gov | NCT06770933 |
|---|---|
| Title | A Phase II, Double-Masked, Randomised, Placebo-Controlled, Parallel Design Study to Evaluate the Efficacy and Safety of Orally Administered VX-01 in Diabetic Retinopathy OF Non-Proliferative Type (NPDR) |
| Results Status | Ongoing |
| ACT or pACT? | This is what FDAAA officially calls an "Applicable Clinical Trial" |
| Start date | Feb. 11, 2025 |
| Completion date | March 31, 2027 |
| Required reporting date | March 30, 2028, midnight |
| Actual reporting date | None |
| Date last checked at ClinicalTrials.gov | April 27, 2026 |
| Days late | None |